Novo Nordisk A S (NVO) EBITDA Margin (2012 - 2016)
Novo Nordisk A S's (NVO) quarterly EBITDA Margin came in at 45.5% in Q2 2016, down 53.0% YoY from 96.8% in Q3 2015, and up 0.59% on a QoQ basis from 45.23% in Q1 2016.
Novo Nordisk A S (NVO) EBITDA Margin (2012 - 2016) Analysis & Trends
Novo Nordisk A S (NVO) has 5 years of EBITDA Margin data on file, last reported at 45.5% in Q2 2016.
- Quarterly EBITDA Margin fell 53.0% year-over-year to 45.5% in Q2 2016, while the trailing twelve-month figure through Jun 2016 was 43.41% (down 56.0% YoY) and the FY2019 annual result came in at 43.01%, up 76.0% from the prior year.
- EBITDA Margin climbed to 45.5% in Q2 2016, from 45.23% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 54.99% in Q1 2015 to a low of 34.0% in Q4 2013.
- A 5-year average of 40.69% and a median of 39.4% in 2012 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2015 — EBITDA Margin surged 1551 bps — and 2016, when it tumbled 976 bps.
- Tracing NVO's EBITDA Margin over 5 years: stood at 36.14% in 2012, then fell by 6 bps to 34.0% in 2013, then increased by 9 bps to 37.12% in 2014, then climbed by 3 bps to 38.42% in 2015, then increased by 18 bps to 45.5% in 2016.
- The last three EBITDA Margin figures came in at 45.5% (Q2 2016), 45.23% (Q1 2016), and 38.42% (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 45.50% |
| Mar 31, 2016 | 45.23% |
| Dec 31, 2015 | 38.42% |
| Sep 30, 2015 | 44.70% |
| Jun 30, 2015 | 46.03% |
| Mar 31, 2015 | 54.99% |
| Dec 31, 2014 | 37.12% |
| Sep 30, 2014 | 38.46% |
| Jun 30, 2014 | 40.40% |
| Mar 31, 2014 | 39.48% |
| Dec 31, 2013 | 34.00% |
| Sep 30, 2013 | 38.98% |
| Jun 30, 2013 | 40.14% |
| Mar 31, 2013 | 37.86% |
| Dec 31, 2012 | 36.14% |
| Sep 30, 2012 | 39.68% |
| Jun 30, 2012 | 39.32% |
| Mar 31, 2012 | 35.99% |